Explore first-line EGFR-mutated NSCLC options, when to intensify beyond osimertinib, and how brain/liver mets, ctDNA, TP53, and comorbidities guide choices.
Back
Prognostic Factors, FLAME and TOP Data, and the Role of ctDNA in Advanced NSCLC with Common EGFR Mutations
Two thoracic medical oncologists review how poor prognostic factors shape frontline treatment selection in EGFR-mutated advanced non-small cell lung cancer (NSCLC) and place data from the TOP study, FLAURA2 study, and FLAME trialinto practice context.
Prognostic Factors, FLAME and TOP Data, and the Role of ctDNA in Advanced NSCLC with Common EGFR Mutations
Episodes
All
All
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma
3
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5